Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Immunome logo
ImmunomeIMNM
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Nektar Therapeutics (NKTR) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $101.48M in Q1 2026.
How has Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale increased by 46.4% year-over-year, from $69.32M to $101.48M.
What is the long-term trend for Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 4 years (2021 to 2025), Nektar Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -29.7% compound annual growth rate (CAGR), from $1.17B to $284.68M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.